<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00529295</url>
  </required_header>
  <id_info>
    <org_study_id>DMR95-IRB-116</org_study_id>
    <nct_id>NCT00529295</nct_id>
  </id_info>
  <brief_title>Titrated Oral Compared With Vaginal Misoprostol for Labor Induction at Term</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China Medical University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to estimate the safety and efficacy of titrated oral
      misoprostol compared with vaginal route for labor induction at term.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oral misoprostol absorption is more rapid and possible more predictable, with a peak serum
      concentration following oral administration of 34 minutes and a half-life of 20-40 minutes.
      Peak serum concentration for vaginal administration is 60-80 minutes, this level being
      sustained for up to four hours. Although the direct local effect of vaginal administration on
      cervical ripening may be advantageous, the shorter half-life of oral delivery may be
      beneficial in the event of uterine hyperstimulation.In order to avoid uterine
      hyperstimulation, it appears reasonable to suggest that oral misoprostol should be
      administered in small, frequent doses, titrated against the uterine response.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The interval from the first misoprostol dose to vaginal delivery and the percentage of women who delivered infants vaginally within 12 and 24 hours of induction. The incidence of tachysystole, hypertonus, uterine hyperstimulation and neonatal outcomes.</measure>
    <time_frame>within the first week after delivery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total dosage of misoprostol and the rate of women given oxytocin, cesarean section and induction failure.</measure>
    <time_frame>The days during induction</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Labor Induction</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Titrated oral misoprostol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vaginal misoprostol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>misoprostol</intervention_name>
    <description>Titrated oral misoprostol: one tablet of 200 microgram was dissolved in water 200 ml, and 20 ml P.O. per one hour for 4 doses, then titrated against uterine response; Vaginal misoprostol: 25 microgram per vagina</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  34 to 42 weeks of gestation

          -  live singleton

          -  Bishop score &lt; or = 6

          -  reassuring fetal heart beat pattern

        Exclusion Criteria:

          -  nonreassuring fetal heart beat pattern

          -  parity ovr five

          -  any contraindication to labor and/or vaginal delivery

          -  uterine scar

          -  suspected placental abruption with abnormal FHR pattern

          -  vaginal bleeding other than &quot;bloody show&quot;

          -  cervical dilatation of &gt; or = 4 cm

          -  uterine contractions &gt; or = 3 in 10 minutes

          -  significant maternal cardiac, renal or hepatic disease

          -  hypersensitivity to misoprostol or prostaglandin analogs
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shi-Yann Cheng, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinal Medical University Beigang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>China Medical University Beigang Hospital</name>
      <address>
        <city>Yun Lin</city>
        <zip>651</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>http://www2.cmu.edu.tw/~cmubh/</url>
    <description>China Medical University Beigang Hospital</description>
  </link>
  <results_reference>
    <citation>Hofmeyr GJ, Alfirevic Z, Matonhodze B, Brocklehurst P, Campbell E, Nikodem VC. Titrated oral misoprostol solution for induction of labour: a multi-centre, randomised trial. BJOG. 2001 Sep;108(9):952-9.</citation>
    <PMID>11563466</PMID>
  </results_reference>
  <verification_date>September 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2007</study_first_submitted>
  <study_first_submitted_qc>September 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2007</study_first_posted>
  <last_update_submitted>September 13, 2007</last_update_submitted>
  <last_update_submitted_qc>September 13, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2007</last_update_posted>
  <keyword>misoprostol</keyword>
  <keyword>labor induction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

